SAN DIEGO --(BUSINESS WIRE)--Nov. 20, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada approval of the t:slim X2™ insulin pump with Basal-IQ™ technology. Basal-IQ technology, a predictive low-glucose suspend

SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: Credit Suisse 28 th Annual Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Nov. 4, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2019 and updated its financial guidance for the year ending December 31, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Nov. 1, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, is supporting the efforts of Beyond Type 1, a global diabetes advocacy organization, in fielding its largest marathon team in history, made up of 30

SAN DIEGO --(BUSINESS WIRE)--Oct. 30, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced presentation of real-world data from pediatric users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend

SAN DIEGO --(BUSINESS WIRE)--Oct. 16, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the landmark Protocol 3 study (DCLP3) of the National

- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes ABBOTT PARK, Ill. and SAN DIEGO , Oct. 15, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) and Tandem Diabetes Care (NASDAQ: TNDM) announced

SAN DIEGO --(BUSINESS WIRE)--Oct. 14, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2019 results after the financial markets close on Monday, November 4, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Sep. 18, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of real-world data from more than 8,000 users of the t:slim X2™ insulin pump with Basal-IQ® predictive low-glucose suspend

SAN DIEGO --(BUSINESS WIRE)--Aug. 29, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will be attending the following upcoming investor conferences: Baird Global Healthcare Conference on Wednesday,

SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2019 and updated its financial guidance for the year ending December 31, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Aug. 1, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced it is offering no-cost feature updates for t:slim X2 insulin pump customers in the United States through the end of 2020.

SAN DIEGO --(BUSINESS WIRE)--Jul. 19, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2019 results after the financial markets close on Thursday, August 1, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Jun. 20, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present at the BMO 2019 Prescriptions for Success Healthcare

Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups SAN FRANCISCO --(BUSINESS WIRE)--Jun. 13, 2019-- Fourth paragraph, fourth sentence of release dated June 9, 2019 , should read: Time spent below 70 mg/dL was 1.4 percent with Control-IQ technology compared to 1.9

Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced positive results from two studies of the

SAN DIEGO --(BUSINESS WIRE)--Jun. 7, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will hold a conference call on Sunday, June 9, 2019 at 8:00pm Eastern Time ( 5:00pm Pacific Time ) following data

SAN DIEGO --(BUSINESS WIRE)--May 13, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a Company update at the following upcoming investor conferences: Bank of America Merrill Lynch Healthcare

SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2019 and updated its financial guidance for the year ending December 31, 2019 .

SAN DIEGO --(BUSINESS WIRE)--Apr. 16, 2019-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2019 results after the financial markets close on Tuesday, April 30, 2019 .